Co-Radiotherapy with Tyrosine Kinase Inhibitors Might Benefit Survival in Hepatoma Patients with Portal Vein Tumor Thrombosis
In this series, 26.9% (43/160) of HCC patients with PVTT underwent combination treatment with TKIs and RT, achieving a median survival of 15.0 months. The contributions of RT were 20% disease control rate and may extend the duration of TKIs use. Therefore, all candidates without contraindications should be considered for combination treatment.
Authors
- Sheng‐Nan Lu (ORCID: https://orcid.org/0000-0002-5493-4752)
- Te‐Sheng Chang (ORCID: https://orcid.org/0000-0002-1581-6948)
- Wei-Ming Lin (ORCID: https://orcid.org/0000-0002-1637-5435)
- Chia‐Hsuan Lai
- Hui‐Ling Huang (ORCID: https://orcid.org/0009-0004-4277-6226)
Institutions
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Chiayi Chang Gung Memorial Hospital (TW)
Publication Details
- Journal
- Biomedical Journal
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1016/j.bj.2025.100904
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00